{{'Wed, 29 Nov 2023 18:29:00 -0500' | dateFormatUsFilter}}
Novo Nordisk takes additional legal actions to help protect US patients from potentially unsafe and ineffective compounded drugs claiming to contain semaglutide that are not FDA approved
Read more
{{'Sat, 11 Nov 2023 08:30:00 -0500' | dateFormatUsFilter}}
Wegovy® (semaglutide) injection 2.4 mg cardiovascular outcomes data presented at the American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine
Read more
{{'Tue, 07 Nov 2023 08:30:00 -0500' | dateFormatUsFilter}}
Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions
Read more
Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.